Literature DB >> 8501989

Discounting in the economic evaluation of health care interventions.

M Krahn1, A Gafni.   

Abstract

Do economic theories that underlie discounting have specific implications for program evaluation in health? In this study, both the contemporary practice and the theoretical foundations of discounting are reviewed. The social discount rate controversy is considered, and the two major concepts (i.e., opportunity cost and time preference) involved in the formulation of a social discount rate are outlined. Also described are the arguments for discounting proposed by thinkers in non-economic disciplines. Finally, the implications of choosing a discount rate for evaluation of individual health care programs are considered. It is argued that the conventional practice of discounting all health care programs at a rate of 5% may not consistently reflect societal or individual preference. Specific recommendations arising from this paper are: 1) given the considerable disagreement at the theoretical level as to the appropriate social discount rate, analysts should be specific about what theoretical approach underlies their choice of rate, especially when the analytic result is sensitive to the discount rate; 2) the discount rate chosen should be appropriate for the perspective of the analysis (social vs. individual vs. institutional, etc.); 3) when appropriate, measures should be taken to avoid double discounting, because some health related outcome measures already incorporate individuals' time preference; and 4) it is suggested that the political process may serve as the appropriate means of reflecting social values in the choice of a discount rate. In addition, the authors argue that a consensus conference approach, with political participation, offers a flexible, pragmatic, and explicit way of synthesizing the empirical, normative, and ethical considerations that underlie choice of a discount rate.

Entities:  

Mesh:

Year:  1993        PMID: 8501989     DOI: 10.1097/00005650-199305000-00003

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  31 in total

1.  An economic model to estimate the relative costs over 20 years of different hip prostheses.

Authors:  K Baxter; G Bevan
Journal:  J Epidemiol Community Health       Date:  1999-09       Impact factor: 3.710

Review 2.  Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies?

Authors:  C Bombardier; A Maetzel
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 3.  Design, analysis and presentation of multinational economic studies: the need for guidance.

Authors:  Francis Pang
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

4.  Highly active antiretroviral therapy: pharmacoeconomic issues in the management of HIV infection.

Authors:  P Sendi; A J Palmer; A Gafni; M Battegay
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 5.  Common errors and controversies in pharmacoeconomic analyses.

Authors:  S Byford; S Palmer
Journal:  Pharmacoeconomics       Date:  1998-06       Impact factor: 4.981

Review 6.  Theoretical arguments for the discounting of health consequences: where do we go from here?

Authors:  Angelina Lazaro
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

7.  Discounting in cost-utility analysis of healthcare interventions: reassessing current practice.

Authors:  Brian J Cohen
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

8.  Effect of discounting on estimation of benefits determined by hepatitis C treatment.

Authors:  Andrea Messori; Valeria Fadda; Dario Maratea; Sabrina Trippoli
Journal:  World J Gastroenterol       Date:  2012-06-21       Impact factor: 5.742

9.  Canadian guidelines for economic evaluation of pharmaceuticals. Canadian Collaborative Workshop for Pharmacoeconomics.

Authors:  G W Torrance; D Blaker; A Detsky; W Kennedy; F Schubert; D Menon; P Tugwell; R Konchak; E Hubbard; T Firestone
Journal:  Pharmacoeconomics       Date:  1996-06       Impact factor: 4.981

10.  Towards a social discount rate for the economic evaluation of health technologies in Germany: an exploratory analysis.

Authors:  Mareike Schad; Jürgen John
Journal:  Eur J Health Econ       Date:  2010-12-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.